The latest installment of the GeneSight® Mental Health Monitor: Special Election Series, shows that as Election Day draws closer, Americans’ anxiety and/or depr...
Americans’ anxiety toward upcoming Presidential election has increased; mental health expert encourages treatment for those who are impacted Phase II of GeneSi...
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election New Findings from Myriad Genetics Reveal One-Third of American...
80% of people diagnosed with anxiety, depression report losing years or decades of time SALT LAKE CITY, April 17, 2024 – An astonishing 44% of Americans feel t...
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test SALT LAKE CITY, April 9, 2024 – Myriad Genetics, Inc. ...
SALT LAKE CITY, Aug. 7 2023 – Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® ...
BIPOC respondents were less likely to seek help than the general population SALT LAKE CITY, July 14, 2023 – Nearly half (47%) of BIPOC (Black, Indigenous, a...
Men are less likely to have a trusted mental healthcare provider than females SALT LAKE CITY, June 5, 2023 – Only 53% of men say they have a trusted mental h...
Nearly twice as many LGBTQ respondents say they are currently diagnosed with depression and/or anxiety than the general population SALT LAKE CITY, June 5, 2023...
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms SALT LAKE CITY, April 19, 2023 – From restr...
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care SALT LAKE CITY, Nov. 17, 2022 – ...
IAVA and Myriad Genetics Host Live Event to Raise Awareness about Genetic Testing and Mental Health Clinical expert to share new research about treatment for...
IAVA Partners with Myriad Genetics New Technologies for Mental Health Treatments Available New York, NY, October 31, 2022 – Iraq and Afghanistan Veterans of...
Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial Study showed PGx ...
Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their men...
With continued commitment to innovation, company makes updates to industry-leading PGx report SALT LAKE CITY, –Myriad Genetics, Inc. (NASDAQ:MYGN), a leader...
GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge SALT LAKE CITY, – O...
SALT LAKE CITY, October 11, 2021– Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won’t seek treatment f...
